Compartir

Control de tabaco Press Releases

26 de Abril de 2022

Nation’s Leading Cancer Advocacy Organization Urges Washington County Voters to Uphold Flavored Tobacco Law on May Primary Ballot

As ballots are mailed out starting Wednesday, April 27, the American Cancer Society Cancer Action Network (ACS CAN) urges Washington County voters to protect youth from Big Tobacco by voting “no” on Measure 34-314, which would repeal the county’s ordinance to end the sale of all flavored tobacco products. Last year, Washington County became the first county in Oregon to end the sale of flavored tobacco, and now the tobacco industry is funding the campaign to try and overturn this law.

19 de Abril de 2022

Brunswick Town Council Votes to End the Sale of All Flavored Tobacco Products

Today, the Brunswick Council voted unanimously to end the sale all flavored tobacco products, including e-cigarettes and menthol flavored products. The American Cancer Society Cancer Action Network (ACS CAN) applauds Town Council members for prioritizing the health of children and historically marginalized communities over Big Tobacco’s interests and bottom line.

15 de Abril de 2022

District Judge Rules FDA Must Provide Status Reports on Premarket Tobacco Product Applications

Today United States District Judge Paul W. Grimm ruled in American Academy of Pediatrics et al v FDA that beginning on April 29 and every 90 days thereafter, the Food and Drug Administration (FDA) must provide regular status reports to the court and the public on the percentage of premarket tobacco product applications (PMTA) the FDA expects to have acted on by June 2022, and beyond.

14 de Marzo de 2022

Los promotores de la lucha contra el cáncer de Arizona se reúnen en el Capitolio para aumentar el acceso a pruebas innovadoras y tratamientos que salvan vidas

Los voluntarios de la Red de Acción Contra el Cáncer de la Sociedad Americana Contra el Cáncer (ACS CAN) de todo Arizona se reunieron en el Capitolio del Estado el lunes para instar a los legisladores a aprobar una legislación que garantice que las pruebas de biomarcadores estén cubiertas por más planes de seguro, incluido Medicaid, cuando los pacientes lo necesiten.